Marc Le Borgne
Director of the Research
University Claude Bernard Lyon 1
Marc Le Borgne has completed his PhD at the age of 31 years from Nantes Atlantic University after Pharmacy studies. He was Associate Professor between 1999 and 2008 in the Faculty of Pharmacy of Nantes. Then he moved to Lyon as a new Professor of medicinal chemistry in the University Claude Bernard Lyon 1. In parallel he became in 2011 the director of EA 4446 “Bioactive Molecules and Medicinal Chemistry” (B2MC), a research group dedicated to Drug Design, Synthesis and Structural Optimization. He has published more than 65 papers in scientific journals and is serving as an editorial board member of Pharmaceuticals (since 2016). He gave some invited lectures abroad (Saarbruecken, Duesseldorf, Oslo, Tromsø, Bergen, Debrecen, Helsinki, Oulu, Rome, Sacramento, Phoenix...). He was laureate of Programme Åsgard (Norway, 2010), Programme SAMPO (Finland, 2014) and Programme TOR (Sweden, 2015). His teaching experience is focused on MedChem (design, synthesis, optimization, SAR analysis, ADMET, therapeutic uses), drug lifecycle, regulatory affairs and industrial property rights at UCBL.
Design, synthesis and structural optimization of functionalized small molecules as anticancer agents (CK2, Dyrks), efflux pump inhibitors (Pg-p, BCRP) and anti-infective agents (CYP51, glycoconjugate vaccines). Diverse scaffolds are studied such as indole, naphthyridine, indeno[1,2-b]indole, 5α/β-pregnane-3,20-dione, 5β-cholan-3-one, peptidomimetics, polysialic acid, polygalacturonic acid. Chemical methodologies are developing using diverse approaches such as microwave irradiation and multicomponent reactions.